Discover a prescription preservative-free treatment option for your moderate to severe dry eye patients

Symptom Relief Results

The once-daily LACRISERT® delivery system can provide all-day lubrication to protect the eye*

The LACRISERT® insert softens within 1 hour and dissolves in 14 to 18 hours†

*In most patients, one LACRISERT® placed into each eye, once daily, is usually effective in providing all-day symptom relief. Some patients may require twice daily use for optimal results.

†Based on pre-clinical data.

Your moderate to severe dry eye patients may benefit from LACRISERT ®if they:

  • Remain symptomatic in spite of frequent use of artificial tears
  • Are unwilling to frequently apply artificial tears or use ointments or gels
  • Want to continue wearing contact lenses
  • Have undergone LASIK or cataract surgery
  • Suffer from dry eye symptoms secondary to Sjögren’s syndrome

Indications and Usage

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

  • LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.
  • Instructions for inserting and removing LACRISERT should be carefully followed.
  • If improperly placed, LACRISERT may result in corneal abrasion. Because LACRISERT may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery.
  • The following adverse reactions have been reported, but were in most instances mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch.

Please see full Prescribing Information for LACRISERT® (hydroxypropyl cellulose ophthalmic insert).

LACRISERT is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2020 Bausch & Lomb Incorporated or its affiliates. LAC.0014.USA.20
CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION
see more

Indications and Usage

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

  • LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.

Important Safety Information

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.